 CAMBRIDGE, Mass., March 01, 2021 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patients body, announced today that it will present at the Cowen 41st Annual Health Care Conference being held virtually from March 1-4, 2021. 